請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/56140
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 賴美淑(Mei-Shu Lai) | |
dc.contributor.author | Ying-Ming Chiu | en |
dc.contributor.author | 邱瑩明 | zh_TW |
dc.date.accessioned | 2021-06-16T05:16:41Z | - |
dc.date.available | 2017-03-12 | |
dc.date.copyright | 2015-03-12 | |
dc.date.issued | 2014 | |
dc.date.submitted | 2014-08-17 | |
dc.identifier.citation | 1. Krishnan E, Fries JF. Reduction in long-term functional disability in rheumatoid arthritis from 1977 to 1998: a longitudinal study of 3035 patients. The American Journal of Medicine 2003; 115(5): 371-6.
2. Kennedy L, Edmunds L, Calin A. The natural history of ankylosing spondylitis. Does it burn out? The Journal of Rheumatology 1993; 20(4): 688-92. 3. McHugh N, Balachrishnan C, Jones S. Progression of peripheral joint disease in psoriatic arthritis: a 5‐yr prospective study. Rheumatology 2003; 42(6): 778-83. 4. Weinblatt ME. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. New England Journal of Medicine 1999; 340(4): 253. 5. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nature Reviews Immunology 2010; 10(5): 301-16. 6. McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess 2007; 11(28): 1-iii-iv. 7. Alonso-Ruiz A, Pijoan JI, Ansuategui E, Urkaregi A, Calabozo M, Quintana A. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskeletal disorders 2008; 9(1): 52. 8. Saad AA, Symmons DP, Noyce PR, Ashcroft DM. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. The Journal of Rheumatology 2008; 35(5): 883-90. 9. Wong GH, Goeddel DV. Tumour necrosis factors α and β inhibit virus replication and synergize with interferons. Nature 1986; 323: 819-22. 10. Kasahara S, Ando K, Saito K, et al. Lack of tumor necrosis factor alpha induces impaired proliferation of hepatitis B virus-specific cytotoxic T lymphocytes. J Virol 2003; 77(4): 2469-76. 11. Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. The Journal of Rheumatology 2003; 30(7): 1624-5. 12. Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003; 62(7): 686-7. 13. Chung S-J, Kim JK, Park M-C, Park Y-B, Lee S-K. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy. The Journal of Rheumatology 2009; 36(11): 2416-20. 14. Zingarelli S, Frassi M, Bazzani C, et al. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature. The Journal of Rheumatology 2009; 36(6): 1188-94. 15. Carroll MB, Bond MI. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Seminars in Arthritis & Rheumatism 2008; 38(3): 208-17. 16. Madonia S, Orlando A, Scimeca D, Olivo M, Rossi F, Cottone M. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis 2007; 13(4): 508-9. 17. Raftery G, Griffiths B, Kay L, Kane D. Chronic viral hepatitis and TNF-α blockade. Rheumatology 2007; 46(8): 1381. 18. Martinez Montiel P, Antonio Solis J, Antonio Chirinos J, A Casis B, Sánchez F, Rodríguez S. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver International 2008; 28(5): 718-20. 19. Matsumoto T, Marusawa H, Dogaki M, Suginoshita Y, Inokuma T. Adalimumab-induced lethal hepatitis B virus reactivation in an HBsAg-negative patient with clinically resolved hepatitis B virus infection. Liver International 2010; 30(8): 1241-2. 20. Sung J-L, Chen D-S, Lai M-Y, et al. Epidemiological study on hepatitis B virus infection in Taiwan. Chinese Journal of Gastroenterology 1984; 1(1): 1-9. 21. Chen C-H, Yang P-M, Huang G-T, Lee H-S, Sung J-L, Sheu J-C. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. Journal of the Formosan Medical Association = Taiwan yi zhi 2007; 106(2): 148-55. 22. Hsu H-Y, Chang M-H, Chen D-S, Lee C-Y, Sung J-L. Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984: A study just before mass hepatitis B vaccination program in Taiwan. J Med Virol 1986; 18(4): 301-7. 23. Tamori A, Koike T, Goto H, et al. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. Journal of Gastroenterology 2011; 46(4): 556-64. 24. Vassilopoulos D, Apostolopoulou A, Hadziyannis E, et al. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis 2010; 69(7): 1352-5. 25. Fotiadou C, Lazaridou E, Ioannides D. Safety of anti‐tumour necrosis factor‐α agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature. Journal of the European Academy of Dermatology and Venereology 2011; 25(4): 471-4. 26. Lan JL, Chen YM, Hsieh TY, et al. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum Dis 2011; 70(10): 1719-25. 27. Charpin C, Guis S, Colson P, et al. Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Research & Therapy 2009; 11(6): R179. 28. Caporali R, Bobbio-Pallavicini F, Atzeni F, et al. Safety of tumor necrosis factor α blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti–hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care & Research 2010; 62(6): 749-54. 29. Giannitti C, Sebastiani GD, Manganelli S, Galeazzi M. Safety of anti-tumor necrosis factor agents in rheumatic potential carriers of occult hepatitis B virus. The Journal Of Rheumatology 2011; 38(4): 780-1. 30. Mori S. Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs. Modern Rheumatology 2011: 1-7. 31. Urata Y, Uesato R, Tanaka D, et al. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Modern Rheumatology 2011; 21(1): 16-23. 32. Cho YT, Chen CH, Chiu HY, Tsai TF. Use of anti-tumor necrosis factor-alpha therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan. The Journal of Dermatology 2012; 39(3): 269-73. 33. Pérez-Alvarez R, Díaz-Lagares C, García-Hernández F, et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore) 2011; 90(6): 359-71. 34. Esteve M, Saro C, González-Huix F, Suarez F, Forné M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis. Gut 2004; 53(9): 1363-5. 35. Oniankitan O, Duvoux C, Challine D, et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. The Journal of Rheumatology 2004; 31(1): 107-9. 36. García-Sánchez MdV, Gómez-Camacho F, Poyato-González A, Iglesias-Flores EM, de Dios-Vega JF, Sancho-Zapatero R. Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection. Inflamm Bowel Dis 2004; 10(5): 701-2. 37. Anelli MG, Torres DD, Manno C, et al. Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab. Arthritis & Rheumatism 2005; 52(8): 2519-20. 38. Ueno Y, Tanaka S, Shimamoto M, et al. Infliximab therapy for Crohn¡¦s disease in a patient with chronic hepatitis B. Digestive Diseases and Sciences 2005; 50(1): 163-6. 39. Wendling D, Auge B, Bettinger D, et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 2005; 64(5): 788-9. 40. Millonig G, Kern M, Ludwiczek O, Nachbaur K, Vogel W. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World Journal of Gastroenterology 2006; 12(6): 974. 41. Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology 2006; 45(10): 1294-7. 42. Esteve M, Loras C, González‐Huix F. Lamivudine resistance and exacerbation of hepatitis B in infliximab‐treated Crohn's disease patient. Inflamm Bowel Dis 2007; 13(11): 1450-1. 43. Sakellariou GT, Chatzigiannis I. Long-term anti-TNFα therapy for ankylosing spondylitis in two patients with chronic HBV infection. Clinical Rheumatology 2007; 26(6): 950-2. 44. Cansu DU, Kalifoglu T, Korkmaz C. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. The Journal of Rheumatology 2008; 35(3): 421-4. 45. Ojiro K, Naganuma M, Ebinuma H, et al. Reactivation of hepatitis B in a patient with Crohn’s disease treated using infliximab. Journal of Gastroenterology 2008; 43(5): 397-401. 46. Kaur PP, Chan VC, Berney SN. Histological evaluation of liver in two rheumatoid arthritis patients with chronic hepatitis B and C treated with TNF-alpha blockade: case reports. Clinical Rheumatology 2008; 27(8): 1069-71. 47. Benucci M, Manfredi M, Mecocci L. Effect of etanercept plus lamivudine in a patient with rheumatoid arthritis and viral hepatitis B. Journal of Clinical Rheumatology 2008; 14(4): 245-6. 48. Li S, Kaur PP, Chan V, Berney S. Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients. Clinical Rheumatology 2009; 28(7): 787-91. 49. Robinson H, Walker-Bone K. Anti-TNF-α therapy for rheumatoid arthritis among patients with chronic hepatitis B infection. Rheumatology 2009; 48(4): 448-50. 50. Kaiser T, Moessner J, Patel K, McHutchison JG, Tillmann HL. Life threatening liver disease during treatment with monoclonal antibodies. BMJ 2009; 338. 51. Conde-Taboada A, Muñoz JP, Muñoz LC, López-Bran E. Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection. Journal of the American Academy of Dermatology 2009; 60(6): 1077. 52. Kuwabara H, Fukuda A, Tsuda Y, Shibayama Y. Precore mutant hepatitis B virus-associated fulminant hepatitis during infliximab therapy for rheumatoid arthritis. Clinical Rheumatology 2010: 1-3. 53. Verhelst X, Orlent H, Colle I, Geerts A, De Vos M, Van Vlierberghe H. Subfulminant hepatitis B during treatment with adalimumab in a patient with rheumatoid arthritis and chronic hepatitis B. Eur J Gastroenterol Hepatol 2010; 22(4): 494. 54. Airo P, Malacarne F, Zingarelli S. The Role of Tumor Necrosis Factor (TNF) in the Immune Response against Hepatitis B Virus (HBV) and the Use of TNF-Blocking Agents in Patients with HBV Infection and Rheumatic Diseases. Journal of Clinical Rheumatology & Musculoskeletal Medicine 2010; 1(2): 1-9. 55. Kuroda T, Wada Y, Kobayashi D, et al. Effect of etanercept and entecavil in a patient with rheumatoid arthritis who is a hepatitis B carrier: a review of the literature. Rheumatology International 2012; 32(4): 1059-63. 56. Wendling D, Di Martino V, Prati C, Toussirot E, Herbein G. Spondyloarthropathy and chronic B hepatitis. Effect of anti-TNF therapy. Joint Bone Spine 2009; 76(3): 308-11. 57. Garcia-Vidal C, Rodriguez-Fernandez S, Teijon S, et al. Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention. Eur J Clin Microbiol Infect Dis 2009; 28(4): 331-7. 58. Ryu HH, Lee EY, Shin K, et al. Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFα agents: A retrospective analysis of 49 cases. Clinical Rheumatology 2012: 1-6. 59. Park YW, Park JH, Bae YS, et al. Hepatic safety of methotrexate in rheumatoid arthritis patients with hepatitis B surface antigen. The Journal of the Korean Rheumatism Association 2001; 8(4): 227-35. 60. Tsai F, Hsieh S, Chen D, Sheu J. Reactivation of hepatitis B virus in rheumatologic patients receiving immunosuppressive agents. Digestive Diseases and Sciences 2006; 51(9): 1627-32. 61. Yazdany J, Calabrese L. Preventing Hepatitis B reactivation in immunosuppressed patients: Is it time to revisit the guidelines? Arthritis Care & Research 2010; 62(5): 585-9. 62. Kim YJ, Bae SC, Sung YK, et al. Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases. The Journal of Rheumatology 2010; 37(2): 346-50. 63. Lee YH, Bae SC, Song GG. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clinical and Experimental Rheumatology 2012; 31(1): 118-21. 64. Tanaka E, Urata Y. Risk of hepatitis B reactivation in patients treated with tumor necrosis factor‐α inhibitors. Hepatology Research 2012; 42(4): 333-9. 65. Mastroianni CM, Lichtner M, Citton R, et al. Current trends in management of hepatitis B virus reactivation in the biologic therapy era. World Journal of Gastroenterology 2011; 17(34): 3881. 66. Mok M, Ng W, Yuen M, Wong R, Lau C. Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. Clinical and Experimental Rheumatology 2000; 18(3): 363-8. 67. Thong BYH, Koh ET, Chng HH, Chow WC. Outcomes of chronic hepatitis B infection in oriental patients with rheumatic diseases. Annals Academy of Medicine Singapore 2007; 36(2): 100-5. 68. Loras C, Gisbert JP, Mínguez M, et al. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut 2010; 59(10): 1340-6. 69. Calabrese L, Zein N, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. British Medical Journal 2006; 65(8): 983. 70. Tan J, Zhou J, Zhao P, Wei J. Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs. Clinical Rheumatology 2012; 31(8): 1169-75. 71. Park SH, Yang SK, Lim YS, et al. Clinical courses of chronic hepatitis B virus infection and inflammatory bowel disease in patients with both diseases. Inflamm Bowel Dis 2012; 18(11): 2004-10. 72. Flowers MA, Heathcote J, Wanless IR, et al. Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy. Annals of Internal Medicine 1990; 112(5): 381. 73. Narvaez J, Rodriguez-Moreno J, Martinez-Aguila M, Clavaguera M. Severe hepatitis linked to B virus infection after withdrawal of low dose methotrexate therapy. The Journal Of Rheumatology 1998; 25(10): 2037. 74. Ito S, Nakazono K, Murasawa A, et al. Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low dose methotrexate therapy in a rheumatoid arthritis patient. Arthritis & Rheumatism 2001; 44(2): 339-42. 75. Hagiyama H, Kubota T, Komano Y, Kurosaki M, Watanabe M, Miyasaka N. Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis. Clinical and Experimental Rheumatology 2004; 22(3): 375-6. 76. Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001; 120(4): 1009-22. 77. Sheen IS, Liaw Y-F, Lin S-M, Chu C-M. Severe clinical rebound upon withdrawal of corticosteroid before interferon therapy: Incidence and risk factors. Journal of Gastroenterology and Hepatology 1996; 11(2): 143-7. 78. Watanabe K, Takase K, Ohno S, Ideguchi H, Nozaki A, Ishigatsubo Y. Reactivation of hepatitis B virus in a hepatitis B surface antigen-negative patient with rheumatoid arthritis treated with methotrexate. Modern Rheumatology 2012; 22(3): 470-3. 79. Gwak GY, Koh K, Kim HY. Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate. Clinical and Experimental Rheumatology 2007; 25(6): 888-9. 80. Kato M, Atsumi T, Kurita T, et al. Hepatitis B virus reactivation by immunosuppressive therapy in patients with autoimmune diseases: risk analysis in hepatitis B surface antigen-negative cases. The Journal Of Rheumatology 2011; 38(10): 2209-14. 81. Sandro V, Francesca C, Maria Serena L. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. The Lancet Oncology 2002; 3(6): 333-40. 82. Mindikoglu AL, Regev A, Schiff ER. Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clinical Gastroenterology and Hepatology 2006; 4(9): 1076-81. 83. Vassilopoulos D, Calabrese LH. Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections. Curr Opin Rheumatol 2007; 19(6): 619. 84. Daniels H, Eddleston A, Alexander G, Williams R, Meager A. Spontaneous production of tumour necrosis factor α and interleukin-1β during interferon-α treatment of chronic HBV infection. The Lancet 1990; 335(8694): 875-7. 85. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996; 4(1): 25-36. 86. Marinos G, Naoumov NV, Rossol S, et al. Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection. Gastroenterology 1995; 108(5): 1453-63. 87. Xunrong L, Wing Yan A, Liang R, Lau GK. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy—pathogenesis and management. Reviews in Medical Virology 2001; 11(5): 287-99. 88. Prey S, Paul C. Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review. British Journal of Dermatology 2009; 160(3): 622-8. 89. Salliot C, Van Der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009; 68(7): 1100-4. 90. Suzuki Y, Uehara R, Tajima C, et al. Elevation of serum hepatic aminotransferases during treatment of rheumatoid arthritis with low-dose methotrexate: risk factors and response to folic acid. Scandinavian Journal of Rheumatology 1999; 28(5): 273-81. 91. Curtis JR, Beukelman T, Onofrei A, et al. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Ann Rheum Dis 2010; 69(01): 43-7. 92. Ahern M, Smith M, Roberts-Thomson P. Methotrexate hepatotoxicity: What is the evidence? Inflamm Res 1998; 47(4): 148-51. 93. Albrecht K, Miiller-Ladner U. Side effects and management of side effects of methotrexate in rheumatoid arthritis. Clinical and Experimental Rheumatology 2010; 28(5): S95-S101. 94. Khan N, Abbas AM, Whang N, Balart LA, Bazzano LA, Kelly TN. Incidence of liver toxicity in inflammatory bowel disease patients treated with methotrexate: A meta‐analysis of clinical trials. Inflamm Bowel Dis 2012; 18(2): 359-67. 95. Ng LC, Lee YY, Lee CK, Wong Sm. A retrospective review of methotrexate‐induced hepatotoxicity among patients with psoriasis in a tertiary dermatology center in Malaysia. Int J Dermatol 2013; 52(1): 102-5. 96. Aithal GP. Hepatotoxicity related to antirheumatic drugs. Nat Rev Rheumatol 2011; 7: 139-50. 97. Jobanputra P, Amarasena R, Maggs F, et al. Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events. BMC Musculoskeletal Disorders 2008; 9(48): 1-7. 98. Khokhar OS, Lewis JH. Hepatotoxicity of agents used in the management of inflammatory bowel disease. Dig Dis 2010; 28(3): 508-18. 99. de Abajo FJ, Montero D, Madurga M, Garcia Rodriguez LA. Acute and clinically relevant drug-induced liver injury: a population based case-control study. British Journal of Clinical Pharmacology 2004; 58(1): 71-80. 100. Helliwell PS, Taylor WJ, Group CS. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs -- comparison of drugs and adverse reactions. The Journal of Rheumatology 2008; 35(3): 472-6. 101. Mancini S, Amorotti E, Vecchio S, Ponz de Leon M, Roncucci L. Infliximab-related hepatitis: discussion of a case and review of the literature. Intern Emerg Med 2010; 5(3): 193-200. 102. Viganò M, Degasperi E, Aghemo A, Lampertico P, Colombo M. Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. Expert Opinion on Biological Therapy 2012; 12(2): 193-207. 103. Coffin CS, Fraser HF, Panaccione R, Ghosh S. Liver diseases associated with anti tumor necrosis factor alpha (TNFα) use for inflammatory bowel disease. Inflamm Bowel Dis 2011; 17(1): 479-84. 104. Suissa S, Ernst P, Hudson M, Bitton A, Kezouh A. Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis. The American Journal of Medicine 2004; 117(2): 87-92. 105. Sokolove J, Strand V, Greenberg JD, et al. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis 2010; 69(9): 1612. 106. Grijalva CG, Kaltenbach L, Arbogast PG, Mitchel EF, Jr., Griffin MR. Initiation of rheumatoid arthritis treatments and the risk of serious infections. Rheumatology 2010; 49(1): 82-90. 107. Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor- antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011; 306(21): 2331-9. 108. Amital H, Arnson Y, Chodick G, Shalev V. Hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate. Rheumatology 2009; 48(9): 1107-10. 109. Fontana RJ, Seeff LB, Andrade RJ, et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology 2010; 52(2): 730-42. 110. Firth D. Bias reduction of maximum likelihood estimates. Biometrika 1993; 80(1): 27-38. 111. Hoekstra M, Van Ede A, Haagsma C, et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. British Medical Journal 2003; 62(5): 423. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/56140 | - |
dc.description.abstract | 背景與目的:抗腫瘤壞死因子藥物為治療類風溼性關節炎、僵直性脊椎炎和乾癬/乾癬性關節炎等自體免疫疾病的新藥。此藥效果卓著,但因為抑制了腫瘤壞死因子使得感染過B型肝炎病毒(HBV)者,其體內HBV病毒容易不斷複製進而導致急性HBV肝炎,此情形不僅發生在HBsAg陽性者身上,HBsAg陰性/anti-HBc陽性者也可能發生。台灣為HBV感染之高盛行區,因此欲針對使用抗腫瘤壞死因子藥物之自體免疫病人:(1)比較不同HBV感染狀態下肝功能異常發生情形(2)了解肝功能異常病例的臨床特徵(3)分析不同HBV感染狀態引起肝功能異常之風險。
研究方法:第一部分為回溯性世代研究,收集2004~2013年間彰化基督教醫院過敏免疫風濕科使用抗腫瘤壞死因子藥物的自體免疫病人,並依照HBsAg陽性、HBsAg陰性/anti-HBc陽性和未感染三種不同感染狀態,比較用藥之後出現肝功能異常的發生率。同時瞭解肝功能異常發生的時間點,並針對發生肝功能異常的病例進行病歷回顧。此外也收集未曾使用過抗腫瘤壞死因子藥物的自體免疫病人,瞭解傳統免疫抑制藥物使用下在不同HBV感染狀態下肝功能異常之發生率。使用標準化率比及其95%信賴區間來檢定不同HBV感染狀態間的肝功能異常發生率是否具統計顯著性差異。第二部分為回溯性世代研究,使用前述研究所建立之抗腫瘤壞死因子藥物使用族群,並排除追蹤未滿一年以及第一年內無肝功能檢驗報告者。計算使用藥物後第一年內肝功能異常之發生率,並針對這些發生肝功能異常的病例,分析其HBV感染狀態分佈以及免疫抑制藥物使用情形,以探討可能影響肝功能異常發生之危險因素。第三部分為鑲嵌式病例對照研究,控制各種干擾因素後,瞭解不同HBV感染狀態對肝功能異常發生的風險。使用第二部分研究所建立之族群,此外凡是相同免疫疾病者及相同用藥年代者歸為同一次族群。在各別次族群中,若開始用藥後一年內有出現肝功能異常者定義為病例組,未出現肝功能異常者定義為對照組,並使用「1比all」的配對方式選取對照組。使用conditional logistic regression,以次族群做為分層變項,分析不同HBV感染狀態和肝功能異常發生之風險,並校正性別、年齡、肝功能異常之過去病史、各種免疫抑制藥物。 結果:(1)以肝功能超過正常值兩倍做為異常的定義下,HBsAg陽性者(n=35)的肝功能異常發生率高於未感染者(n=155),年齡性別標準化發生率為19.6每百人年比上6.5每百人年(標準化率比 3.02,95%信賴區間1.23-7.46),達統計顯著性差異;而HBsAg陰性/anti-HBc陽性者(n=282)的發生率和未感染的標準化發生率分別為6.8每百人年和6.5每百人年(標準化率比1.05,95%信賴區間0.49-2.25),未達統計顯著性差異。有79%的病人其第一次肝功能異常出現的時間是在開始用藥的第一年內。(2)總共有390位抗腫瘤壞死因子藥物使用者納入分析,在使用藥物的第ㄧ年出現肝功能異常的病例有31位,發生率7.9%。這些病例中,女性佔64.5%(n=20),平均年齡45.5歲;HBsAg陽性者(n=8)佔25.8%,HBsAg陰性/anti-HBc陽性者(n=14)佔45.2%,未感染者(n=9)佔29.0%。有肝功能異常的過去病史者佔25.8%(n=8)。有使用methotrexate者佔67.7%(n=21),當中有併用葉酸和沒有併用葉酸者分別是36.7%(n=12)和29.0%(n=9)。(3)總共有368位病人納入分析。HBsAg陽性者出現肝功能異常的風險是未感染者的6.33倍 (95%信賴區間1.79-23.52),達統計顯著性差異;HBsAg陰性/anti-HBc陽性是未感染者的0.88倍(95%信賴區間0.29-2.87),未達統計顯著性差異。肝功能異常之過去病史和單獨使用methotrexate未併用葉酸,是影響肝功能異常發生的主要危險因素。 結論:本研究以醫院資料為基礎所做的回溯性世代研究發現,自體免疫病人使用抗腫瘤壞死因子藥物時,HBsAg陽性者出現肝功能異常的風險大約是未感染者的6倍,而HBsAg陰性/Anti-HBcAb陽性者則沒有顯著較高的肝功能異常風險。而肝功能異常的過去病史以及單獨使用MTX未併用葉酸,是影響肝功能異常發生的主要危險因素。 | zh_TW |
dc.description.abstract | Background and objective: Anti-tumor necrosis factor (anti-TNF) agents are new drugs for the treatment of autoimmune disease, such as rheumatoid arthritis, ankylosing spondylitis and psoriasis/psoriatic arthritis. Although anti-TNF agents have good efficacy, this class of drugs could suppress tumor necrosis factor which results in the duplication of hepatitis B virus (HBV) in patients with prior HBV infection, increasing the possibility of acute viral hepatitis. This happens not only in HBsAg-positive patients, but can also occur in HBsAg-negtive/anti-HBc-positive patients. As Taiwan is an endemic area for HBV infection, this study will focus on the analysis of autoimmune patients treated by anti-TNF agents to (1) compare the incidence of liver function abnormality in different HBV infection status, (2) understand the clinical characteristics of case with liver function abnormality, and (3) analyze the risk of liver function abnormality of each HBV infection status.
Method: The first part of the study was a retrospective cohort study which collected all autoimmune patients who were treated by anti-TNF agents in Department of Rheumatology of Changhua Christian Hospital from 2004 to 2013. The incidence of liver function abnormality was compared between patients tested HBsAg-positive, HBsAg-negtive/anti-HBc-positive, and uninfected, and the onset time of liver function abnormality were analyzed. In addition, chart review of those patients who developed liver function abnormality was performed. Autoimmune patients who only used traditional immunosuppressant were also collected, and the incidence of liver function abnormality of different HBV infection status was analyzed in these patients. Standardized rate ratio (SPR) and 95% confidence interval (95% CI) were used to test the statistically significant difference of liver function abnormality incidence between different HBV infection status groups. The second part of the study was a retrospective cohort using the study population from the first part but excluding patients who were followed less than one year or lacked liver function data in the first year of treatment. The incidence of liver function abnormality in first year was calculated. Furthermore, HBV infection status and immunosuppressant use in the cases of liver function abnormality was analyzed to explore the possible risk factors of liver function abnormality. The third part of the study was a nested case-control study which controlled all potential confounders to estimate the risk of liver function abnormality of each HBV infection status. Study group from the second part of the study was used. Patients were categorized in the same subgroup if they had the same underlying autoimmune disease and started anti-TNF agent therapy in the same calendar year. In each subgroup, those patients developed liver function abnormality in the first year of anti-TNF treatment were defined as case group, and those who did not were defined as control group. '1-to-all' matching was used to select the controls. With subgroup as the stratum variable in model analysis, conditional logistic regression was used to estimate the odds ratio for liver function abnormality of each HBV infection status after gender, age, past history of liver function abnormality, and immunosuppressant use were adjusted. Result: (1) When the liver function abnormality was defined as >2-fold the upper limit of normal, HBsAg-positive patients (n=35) had significantly higher incidence of liver function abnormality than uninfected (n=155). The gender- and age-adjusted incidence rate were 19.6 per 100 person-year (PY) and 6.5 per 100 PY respectively, (SRR=3.02, 95% CI=1.23-7.46) and they were statistically different. On the other hand, incidence for HBsAg-negtive/anti-HBc-positive patients and uninfected were not significantly different from each other (6.8 per 100 PY and 6.5 per 100 PY respectively; SRR=1.05, 95% CI=0.49-2.25). 79% of the patients developed first incident of liver function abnormality during the first year of anti-TNF treatment. (2) Among the 390 anti-TNF users who were included for the analysis, 31 developed liver function abnormality in the first year of anti-TNF treatment, an incidence rate of 7.9%. Among those cases with liver function abnormality, 64.5% were female (n=14), mean age was 45.5 years. Furthermore, 25.8% were HBsAg positive (n=8), 45.2% were HBsAg-negtive/anti-HBc-positive (n=14), and uninfected were 29.0% (n=9). 61.3% of the cases were rheumatoid arthritis (n=19), 45.2% of the cases started using anti-TNF agents in 2010~2012 (n=14). 25.8% of the cases had past history of liver function abnormality (n=8). 67.7% of the cases used methotrexate (n=21); of those, 36.7% of the cases combined with folic acid (n=12) and 29.0% of the cases did not combine with folic acid (n=9). (3) A total of 368 patients were included for analysis. The HBsAg-positive patients had significantly higher risk of liver function abnormality than the uninfected (OR=6.33, 95% CI=1.79-23.52). However, the association of liver function abnormality between HBsAg-negtive/anti-HBc-positive and uninfected was statistically insignificant (OR=0.88, 95% CI=0.29-2.87). Past history of liver function abnormality and treatment with methotrexate alone without folic acid were the two major risk factors for liver function abnormality in those patients. Conclusion: In this hospital-based retrospective cohort study of autoimmune patients treated by anti-TNF agents, the risk for liver function abnormality in HBsAg-positive patients was about 6-fold higher than uninfected, and HBsAg-negtive/anti-HBc-positive patients was not associated with higher risk of liver function abnormality. Past history of liver function abnormality and methotrexate only treatment without folic acid were the major risk factors for liver function abnormality. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T05:16:41Z (GMT). No. of bitstreams: 1 ntu-103-F93842009-1.pdf: 510880 bytes, checksum: 7ddcee2d5f3cf491cb239fbba0bad754 (MD5) Previous issue date: 2014 | en |
dc.description.tableofcontents | 中文摘要...........................................I
英文摘要.............................................III 第一章 前言 1 第二章 文獻回顧 2 第一節 HBV病毒對抗腫瘤壞死因子藥物使用者肝功能影響之相關研究 2 一、HBsAg陽性 2 二、HBsAg陰性/anti-HBc陽性 7 第二節 HBV病毒對免疫抑制藥物使用者肝功能影響之相關研究 10 一、HBsAg陽性 10 二、HBsAg陰性/anti-HBc陽性 12 第三節 抗腫瘤壞死因子藥物和免疫抑制藥物影響HBV病毒之機轉 13 第四節 其它藥物引發肝功能異常之機轉及相關研究 14 第五節 文獻回顧小結 16 第六節 研究目的 16 第三章 材料與方法 17 第一節 使用抗腫瘤壞死因子藥物之自體免疫病人中不同HBV感染狀態肝功能異常發生情形之分析 17 一、研究設計 17 二、研究族群與資料來源 17 四、肝功能異常定義與臨床描述 20 五、其它研究變項 21 六、肝功能異常發生率 21 七、統計分析 22 第二節 使用抗腫瘤壞死因子藥物之自體免疫病人中肝功能異常發生率與病例之臨床分析 23 一、研究設計 23 二、研究族群 23 三、肝功能異常定義 24 三、肝功能異常定義 25 四、研究變項與統計方法 25 第三節 使用抗腫瘤壞死因子藥物之自體免疫病人中引發肝功能異常之危險因素分析—探討HBV感染狀態之影響 26 一、研究設計 26 二、研究族群 26 三、依變項:肝功能異常 29 四、研究變項:HBV感染狀態 29 五、控制變項 29 六、分層變項 30 七、統計分析 31 八、敏感性分析 32 第四章 結果 33 第一節 使用抗腫瘤壞死因子藥物之自體免疫病人中不同HBV感染狀態肝功能異常發生情形之分析 33 一、研究族群基本資料與HBV感染狀態分佈之描述性分析 33 二、肝功能異常之發生情形分析 37 三、傳統免疫抑制藥物使用者之肝功能異常發生率 46 第二節 使用抗腫瘤壞死因子藥物之自體免疫病人中肝功能異常發生率與病例之臨床分析 50 一、研究族群之描述性分析與肝功能異常發生率 50 二、肝功能異常病例之臨床特徵與併用藥物分析 52 第三節 使用抗腫瘤壞死因子藥物之自體免疫病人中引發肝功能異常之危險因素分析—探討HBV感染狀態之影響 54 一、研究族群基本資料與用藥情形之描述性分析 54 二、不同HBV感染狀態別和抗腫瘤壞死因子藥物使用者肝功能異常之關係 64 三、HBV感染狀態與危險因素之交互作用 67 四、敏感性分析 70 第五章 討論 72 第一節 HBsAg陽性對肝功能異常之影響 72 第二節 HBsAg陰性/Anti-HBcAb陽性對肝功能異常之影響 73 第三節 其他危險因素對肝功能異常之影響 74 第四節 肝功能異常病例之病歷回顧 74 第五節 本研究方法學之討論 75 第六節 研究限制 76 第七節 未來研究方向 77 第六章 結論 78 參考文獻 79 附錄 86 附錄I HBV血清學檢驗方式之敏感度與特異度 86 附錄II 抗腫瘤壞死因子藥物使用者中肝功能異常病例之病歷回顧 87 附錄III 抗腫瘤壞死因子藥物使用者中肝功能異常病例之病歷回顧摘要 89 附錄IV 傳統免疫抑制藥物使用者中肝功能異常病例之病歷回顧 91 附錄V 傳統免疫抑制藥物使用者中肝功能異常病例之病歷回顧摘要 93 | |
dc.language.iso | zh-TW | |
dc.title | B型肝炎病毒對自體免疫病人使用抗腫瘤壞死因子藥物者肝功能影響之研究 | zh_TW |
dc.title | Study of the role of hepatitis B virus on liver function abnormality in patients with autoimmune disease using anti-tumor necrosis factor agents | en |
dc.type | Thesis | |
dc.date.schoolyear | 102-2 | |
dc.description.degree | 博士 | |
dc.contributor.coadvisor | 陳建煒(Kin-Wei Chan) | |
dc.contributor.oralexamcommittee | 藍忠亮,劉俊人,李文宗,劉仁沛,張家勳 | |
dc.subject.keyword | 抗腫瘤壞死因子藥物,B型肝炎病毒,自體免疫疾病,回溯性世代研究,鑲嵌式病例對照研究, | zh_TW |
dc.subject.keyword | anti-tumor necrosis factor (anti-TNF) agents,hepatitis B virus (HBV),autoimmune disease,retrospective cohort study,nested case-control study, | en |
dc.relation.page | 94 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2014-08-18 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 流行病學與預防醫學研究所 | zh_TW |
顯示於系所單位: | 流行病學與預防醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-103-1.pdf 目前未授權公開取用 | 498.91 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。